650624-42-3

Basic information

• Product Name: L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl-, methyl ester
• CAS NO: 650624-42-3
• Molecular Formula: C24H37N3O8
• Molecular Weight: 495.573
• Mol File: 650624-42-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl-, methyl ester(650624-42-3)
• EPA Substance Registry System: L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl-, methyl ester(650624-42-3)

Safety Data

• Hazardous Substances Data: 650624-42-3(Hazardous Substances Data)

Usage

General Description

L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl-, methyl ester is a chemical compound with a complex molecular structure. It is a methyl ester derivative of the amino acids leucine, tyrosine, and serine. L-Leucine, N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-L-seryl-, methyl ester is primarily used in research and pharmaceutical applications for its potential in protein synthesis and regulation. It is also used in the development of new drugs and therapeutics, particularly in the field of oncology and immunology. Additionally, this compound has shown potential in enhancing muscle growth and repair, making it a promising candidate for use in sports nutrition and supplements.

Upstream product

• 3978-80-1 Boc-Tyr-OH 
• 75816-57-8 Ser-Leu-OMe hydrochloridel 
• 7517-19-3 methyl (L)-leucinate hydrochloride 
• 85328-90-1 (S)-2-((S)-2-tert-butoxycarbonylamino-3-hydroxypropanoylamino)-4-methylpentanoic acid methyl ester 

Relevant articles and documents

The synthesis, distribution, and anti-hepatic cancer activity of YSL

(I) HCl/CH3OH; (II) DCC/HOBt/NMM with corresponding carboxyl component; (III) HCl/CH3CO2C2H5 (6 mol/L); (IV) NaOH/H2O/CH3OH; (V) 3H2 and 10% Pd/C. YSL was prepared stepwise from C terminal to N terminal with the side chain un-protective amino acids, Boc-Leu-OMe, Boc-Ser-OH, and Boc-Tyr-OH, as the starting materials in 39.5% total yield (31.2 g/per batch). With the side chain un-protective Boc-(3,5-dibromo)-Tyr-OH and HClA·Ser-Leu-OMe as the starting materials (3,5-3H-Tyr)-Ser-Leu-OH was obtained in 29% yield. The determination of radioactive quantity in the urine and feces indicated that even after the administration for 130 h only 8.4% (5.35% in urine and 3.05% in feces) of total radioactive quantity from the metabolite of [3,5-3H-Tyr]-Ser-Leu-OH were monitored. The distribution study revealed the relative accumulation level of the individual tissue was arranged in the sequence of spleen > liver > kidney > lung > heart > muscle > brain. Selecting hepatic cancer as the target YSL significantly increased the survival time of H22 tumor cells implanted mice.